TR115

DRUG3 trials

Sponsors

Tarapeutics Science Inc.

Conditions

Advanced Solid TumorEndometrial CancerNK T-Cell LymphomaNon-Hodgkin's Lymphoma RefractoryNon-Hodgkin's Lymphoma, RelapsedOvarian Clear Cell CarcinomaPTCLStomach Cancer Recurrent

Phase 1

TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors

RecruitingNCT05650580

Tarapeutics Science Inc.Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Advanced Solid Tumor

Start: 2023-04-23End: 2025-12-30Target: 26Updated: 2024-05-14

Phase 2

TR115 in ARID1A-Mutated Advanced Solid Tumors

Not yet recruitingNCT07793318

Tarapeutics Science Inc.Ovarian Clear Cell Carcinoma, Endometrial Cancer, Stomach Cancer Recurrent +1

Start: 2026-09-20End: 2029-05-01Target: 50Updated: 2026-08-28

Phase 3

TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma

Not yet recruitingNCT07639879

Tarapeutics Science Inc.PTCL, NK T-Cell Lymphoma

Start: 2026-07-30End: 2030-07-30Target: 180Updated: 2026-06-10

Related Papers

A phase I study of the EZH2 inhibitor TR115 in patients with relapsed/refractory non-Hodgkin's lymphomas and advanced solid tumors.

Journal of Clinical Oncology2025-05-28